Quick-Med Technologies Inc. announced that it has amended the license previously granted to Viridis BioPharma to include a new antimicrobial polyurethane foam dressing that utilizes Quick-Med's proprietary NIMBUS(R) technology and that Viridis has received approval from the Food and Drug Administration of India to manufacture and market the dressings. This is the first of several NIMBUS advanced wound care formats that are in development. Viridis BioPharma plans to commercialize a broad line of wound care products that incorporate Quick-Med's unique NIMBUS antimicrobial technology including gauze pads, gauze rolls and foam dressings, under the trade name of Microgauze(TM) and Microfoam(TM) wound dressings. Viridis has completed a manufacturing expansion to produce the new dressings and plans to have the dressings on the market before the end of the second quarter of 2012. Laboratory testing has demonstrated that Microfoam is highly effective against even the most difficult Gram-negative species of pathogenic bacteria. Additionally, Viridis has conducted a pilot clinical trial in Mumbai that confirmed continuous infection control and the exudate absorption property of this non-leaching antimicrobial dressing over days of use.